Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascentage
Pharma
MediLink, Takeda, Ascentage and China NMPA—Fierce Pharma Asia
BioNTech and MediLink's ADC was put on a hold. Takeda gained an option to license a CML drug. Regulators from China and the U.S. met at FDA offices.
Angus Liu
Jun 21, 2024 8:23am
Takeda circles Ascentage's Scemblix challenger for up to $1.3B
Jun 14, 2024 11:30am
Pfizer, Gilead-Yuhan and more—FiercePharmaAsia
Jan 11, 2019 11:02am
FiercePharmaAsia—Pfizer, China-India alliance, Sinovant and more
Jul 20, 2018 9:58am
